JP2021511058A5 - - Google Patents

Info

Publication number
JP2021511058A5
JP2021511058A5 JP2020540397A JP2020540397A JP2021511058A5 JP 2021511058 A5 JP2021511058 A5 JP 2021511058A5 JP 2020540397 A JP2020540397 A JP 2020540397A JP 2020540397 A JP2020540397 A JP 2020540397A JP 2021511058 A5 JP2021511058 A5 JP 2021511058A5
Authority
JP
Japan
Prior art keywords
antigen
amino acid
acid sequence
seq
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020540397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511058A (ja
JP7834965B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014978 external-priority patent/WO2019147831A1/en
Publication of JP2021511058A publication Critical patent/JP2021511058A/ja
Publication of JP2021511058A5 publication Critical patent/JP2021511058A5/ja
Priority to JP2023177262A priority Critical patent/JP2024009962A/ja
Application granted granted Critical
Publication of JP7834965B2 publication Critical patent/JP7834965B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020540397A 2018-01-26 2019-01-24 抗tmprss2抗体および抗原結合断片 Active JP7834965B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177262A JP2024009962A (ja) 2018-01-26 2023-10-13 抗tmprss2抗体および抗原結合断片

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622292P 2018-01-26 2018-01-26
US62/622,292 2018-01-26
PCT/US2019/014978 WO2019147831A1 (en) 2018-01-26 2019-01-24 Anti-tmprss2 antibodies and antigen-binding fragments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177262A Division JP2024009962A (ja) 2018-01-26 2023-10-13 抗tmprss2抗体および抗原結合断片

Publications (3)

Publication Number Publication Date
JP2021511058A JP2021511058A (ja) 2021-05-06
JP2021511058A5 true JP2021511058A5 (enExample) 2022-01-21
JP7834965B2 JP7834965B2 (ja) 2026-03-25

Family

ID=66102175

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540397A Active JP7834965B2 (ja) 2018-01-26 2019-01-24 抗tmprss2抗体および抗原結合断片
JP2023177262A Pending JP2024009962A (ja) 2018-01-26 2023-10-13 抗tmprss2抗体および抗原結合断片

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177262A Pending JP2024009962A (ja) 2018-01-26 2023-10-13 抗tmprss2抗体および抗原結合断片

Country Status (26)

Country Link
US (3) US10941213B2 (enExample)
EP (1) EP3638698B1 (enExample)
JP (2) JP7834965B2 (enExample)
KR (2) KR102911478B1 (enExample)
CN (2) CN120290578A (enExample)
AU (2) AU2019211406C1 (enExample)
BR (1) BR112020015112A2 (enExample)
CA (1) CA3089377A1 (enExample)
CY (1) CY1124182T1 (enExample)
DK (1) DK3638698T3 (enExample)
ES (1) ES2864529T3 (enExample)
HR (1) HRP20210876T1 (enExample)
HU (1) HUE054403T2 (enExample)
IL (2) IL312961A (enExample)
LT (1) LT3638698T (enExample)
MA (1) MA46731B1 (enExample)
MD (1) MD3638698T2 (enExample)
MX (2) MX2020007888A (enExample)
PL (1) PL3638698T3 (enExample)
PT (1) PT3638698T (enExample)
RS (1) RS61825B1 (enExample)
SG (1) SG11202006898TA (enExample)
SI (1) SI3638698T1 (enExample)
SM (1) SMT202100307T1 (enExample)
WO (1) WO2019147831A1 (enExample)
ZA (1) ZA202004494B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI701258B (zh) * 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3638698B1 (en) * 2018-01-26 2021-03-03 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
MX2022008901A (es) 2020-01-24 2022-08-16 Regeneron Pharma Conjugados de proteinas-compuestos antivirales.
AU2021219671A1 (en) * 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2021211406A1 (en) * 2020-04-13 2021-10-21 Maddon Advisors Llc Tmprss2-targeted compositions and methods for treating covid-19
IL297237B2 (en) 2020-04-17 2025-08-01 Regeneron Pharma Detection assays for coronavirus neutralizing antibodies
WO2021212101A1 (en) 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
US12097212B2 (en) * 2020-06-08 2024-09-24 Brigham Young University Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
WO2021255217A1 (en) 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
CN111986818A (zh) * 2020-08-21 2020-11-24 南通大学 一种基于tmprss2的新冠covid-19治疗药物筛选系统
EP4208197A1 (en) * 2020-09-04 2023-07-12 Rutgers, The State University of New Jersey Sars-cov-2 vaccines and antibodies
CN112795583A (zh) * 2020-11-16 2021-05-14 上海大学 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法
WO2022115503A1 (en) 2020-11-25 2022-06-02 Dupont Nutrition Biosciences Aps Treatment and prevention of coronavirus infection
CN112538494A (zh) * 2020-12-08 2021-03-23 武汉华美生物工程有限公司 一种tmprss2突变体蛋白及其表达载体、表达工程菌和制备方法
WO2022133182A1 (en) * 2020-12-18 2022-06-23 Chan Zuckerberg Biohub, Inc. Method of treating coronavirus infection
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
JPWO2023199943A1 (enExample) * 2022-04-12 2023-10-19
WO2023220712A1 (en) * 2022-05-13 2023-11-16 The Trustees Of Columbia University In The City Of New York Host proteases essential for parainfluenza spread in the human lung: potential targets for antiviral interventions
CN116003611B (zh) * 2022-08-17 2024-02-27 中南大学湘雅医院 抗tmprss2抗体及其用途
EP4724502A1 (en) * 2023-06-08 2026-04-15 Institut Pasteur Single domain antibodies directed against human transmembrane- serine protease 2 (tmprss2)
EP4784801A1 (en) * 2023-09-28 2026-08-05 The Regents of the University of California Methods for identifying and treating diseases characterized by allele specific expression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE60138465D1 (de) * 2000-07-12 2009-06-04 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2008127347A1 (en) 2006-07-21 2008-10-23 Diadexus, Inc. Pro115 antibody compositions and methods of use
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
ES2886123T3 (es) * 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
EP2838558A1 (en) * 2012-04-16 2015-02-25 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
WO2018175749A2 (en) * 2017-03-22 2018-09-27 Children's Medical Center Corporation Lrp1 binding agents and uses thereof
EP3638698B1 (en) * 2018-01-26 2021-03-03 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments

Similar Documents

Publication Publication Date Title
IL312961A (en) Anti-tmprss2 antibodies and antigen-binding fragments
Wang et al. The state of the art of bispecific antibodies for treating human malignancies
JP2021524267A5 (enExample)
JP2023513124A5 (enExample)
JP2021516973A5 (enExample)
JP2021533726A5 (enExample)
JP2021516975A5 (enExample)
JP2021515568A5 (enExample)
JP2020532965A5 (enExample)
FI3625259T3 (fi) Anti-sirp-alfa vasta-aineet
JP2018527919A5 (enExample)
RU2018100424A (ru) Комбинированная терапия для лечения злокачественной опухоли
FI3459597T3 (fi) Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini
JP2024527606A5 (enExample)
JP2016536020A5 (enExample)
JP2017506067A5 (enExample)
JP2021513844A5 (enExample)
JP2014158469A5 (enExample)
JP2009525764A5 (enExample)
JP2015502138A5 (enExample)
JP2018536632A5 (ja) B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子
JP2017535246A5 (enExample)
JP2024016024A5 (enExample)
RU2013106217A (ru) Гибридный белок из антитела против мнс и противовирусного цитокина
RU2018107693A (ru) Комбинированные виды лечения и их варианты применения и способы